Why the study?
Does reducing dynamin 2 (DNM2) rescue DNM2-related dominant centronuclear myopathy?
Does reducing dynamin 2 (DNM2) rescue DNM2-related dominant centronuclear myopathy?
Reducing DNM2 by targeting both alleles rescues DNM2-related dominant centronuclear myopathy, suggesting a potential therapeutic strategy for dominant diseases.
Answers are grounded in this paper and cite their sources.
Animal evidence supports DNM2 reduction in myopathy models; human trials needed before any clinical consideration.
mutations, and it provides a common therapeutic strategy for several forms of centronuclear myopathy. Furthermore, we provide an example of treating a dominant disease by targeting both alleles, suggesting that this strategy may be applied to other dominant diseases.
No takes yet. Share an insight, caveat, or question.
Buono et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: